Evidence map›Paper›PMID 38519799›Full record

ArticleLeukemia2024

Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.

Thomas Burmeister, Aeint-Steffen Ströh, Britta Kehden, Heiko Trautmann, Claus Meyer, Rolf Marschalek, Patrizia Larghero, Stefan Schwartz, Björn Steffen, Bernd Spriewald and 10 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Thomas Burmeister *Department of Hematology, Oncology and Tumor Immunology, CVK, Charité-Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. thomas.burmeister@charite.de.ORCID 0000-0003-4843-2876
Aeint-Steffen Ströh *University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.ORCID 0000-0002-7463-5354
Britta KehdenUniversity Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.
Heiko TrautmannUniversity Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.ORCID 0000-0002-9000-4747
Claus MeyerDiagnostic Center of Acute Leukemia (DCAL), Institute of Pharmaceutical Biology, Goethe University, Frankfurt, Germany.
Rolf MarschalekDiagnostic Center of Acute Leukemia (DCAL), Institute of Pharmaceutical Biology, Goethe University, Frankfurt, Germany.ORCID 0000-0003-4870-3445
Patrizia LargheroDiagnostic Center of Acute Leukemia (DCAL), Institute of Pharmaceutical Biology, Goethe University, Frankfurt, Germany.
Stefan SchwartzDepartment of Hematology, Oncology and Tumor Immunology, CBF, Charité Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0001-8833-5793
Björn SteffenDepartment of Medicine II, Goethe University, University Hospital, Frankfurt, Germany.ORCID 0009-0002-6693-4079
Bernd SpriewaldUniversity Hospital Erlangen, Department of Internal Medicine 5, Hematology and Oncology, Erlangen, Germany.
Thomas HeinickeDepartment of Hematology and Oncology, Otto-von-Guericke University Hospital, Magdeburg, Germany.ORCID 0000-0002-4049-7854
Nadja JäkelDepartment of Hematology, Oncology, University Hospital, Halle/Saale, Germany.ORCID 0000-0001-6162-515X
Jörg WestermannDepartment of Hematology, Oncology and Tumor Immunology, CVK, Charité-Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Kathrin NachtkampDepartment of Hematology, Oncology, University Hospital of Düsseldorf, Düsseldorf, Germany.
Andreas ViardotDepartment of Hematology, Oncology, University Hospital Ulm, Ulm, Germany.
Max S ToppDepartment of Hematology, Oncology, University Hospital Würzburg, Würzburg, Germany.
Martin NeumannUniversity Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.
Claudia D BaldusUniversity Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.ORCID 0000-0002-0748-834X
Nicola GökbugetDepartment of Medicine II, Goethe University, University Hospital, Frankfurt, Germany.
Monika BrüggemannUniversity Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 4134905Deutsche Forschungsgemeinschaft (German Research Foundation) 444949889
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Gene RearrangementHistone-Lysine N-MethyltransferaseMyeloid-Lymphoid Leukemia ProteinNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentAdultAgedFemaleHumansMaleMiddle AgedPrognosisYoung AdultHistone-Lysine N-MethyltransferaseKMT2A protein, humanMyeloid-Lymphoid Leukemia Protein

Identifiers

PMID38519799
PMCPMC11216977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.